The Independent Pharmacy: UK's Pharmaceuticals & Medication Source

Category: Healthcare and Pharmaceuticals - Page 2

post-image
Dec, 5 2025

International Pharmacovigilance: How Global Safety Monitoring Is Being Harmonized

Eldric Moreland
11
Global drug safety monitoring is becoming more aligned through ICH guidelines, AI, and shared data systems. Learn how harmonization speeds up safety alerts, cuts costs, and protects patients worldwide-even in low-resource countries.
post-image
Dec, 3 2025

Future Approaches to Changing Perceptions of Generic Drugs

Eldric Moreland
15
Generic drugs save billions annually but still face public distrust. Learn how new education strategies, biosimilars, and technology are reshaping perceptions and building trust in affordable medications.
post-image
Dec, 2 2025

Hospital Formularies: How Systems Choose Generic Drugs

Eldric Moreland
12
Hospital formularies use evidence-based processes to select generic drugs that balance safety, effectiveness, and cost. Learn how Pharmacy and Therapeutics committees make these critical decisions and why they matter for patient care.
post-image
Dec, 2 2025

What Are Authorized Generics? A Complete Breakdown of How They Work and Why They Matter

Eldric Moreland
10
Authorized generics are brand-name drugs sold without the brand name, made by the same manufacturer with identical ingredients. They offer lower prices while maintaining the exact formulation-unlike traditional generics. Learn how they work, why they exist, and how to get them.
post-image
Dec, 1 2025

FDA Listing for Biosimilars: How They Are Evaluated and Approved

Eldric Moreland
14
The FDA doesn't rate biosimilars like grades-they approve them through a strict scientific process to ensure they're highly similar to biologics with no clinically meaningful differences. Here's how it works, why they're not generics, and what you need to know about interchangeability.
post-image
Nov, 27 2025

Biologic Patent Protection: When Biosimilars Can Enter the U.S. Market

Eldric Moreland
11
Biologic patent protection in the U.S. gives drugmakers 12 years of exclusivity before biosimilars can enter, delaying affordable alternatives. Learn how the BPCIA, patent thickets, and global differences affect patient access and drug prices.
post-image
Nov, 17 2025

180-Day Exclusivity in Generic Drug Market Entry: How Patent Law Shapes Drug Prices

Eldric Moreland
9
The 180-day exclusivity rule under the Hatch-Waxman Act was meant to speed up generic drug entry, but delays by first applicants often block competition for years-keeping prices high and patients waiting.
post-image
Oct, 26 2025

FDA REMS Programs: Complete Guide to Risk Evaluation and Mitigation Strategies

Eldric Moreland
12
A clear, practical guide to FDA REMS programs, covering why they exist, key elements, real‑world examples, costs, challenges, and future digital trends.
post-image
Oct, 25 2025

Dilantin (Phenytoin) vs Common Antiepileptic Alternatives - A Detailed Comparison

Eldric Moreland
9
A thorough side‑by‑side review of Dilantin (phenytoin) versus five common antiepileptic alternatives, covering mechanisms, side‑effects, interactions, and how to choose the right drug.
post-image
Oct, 21 2025

Azelastine vs Other Antihistamines: Comprehensive Comparison

Eldric Moreland
15
A practical guide comparing azelastine nasal spray with popular oral antihistamines, covering how they work, side‑effects, onset, duration, and how to choose the right option for allergies.

Categories

Latest Courses

Popular Tags